<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02090387</url>
  </required_header>
  <id_info>
    <org_study_id>BL20</org_study_id>
    <nct_id>NCT02090387</nct_id>
    <nct_alias>NCT02238600</nct_alias>
  </id_info>
  <brief_title>Evaluation of an Oral Nutritional Supplement on Lean Body Mass in Healthy Older Subjects.</brief_title>
  <official_title>Evaluation of a Complete Oral Nutritional Supplement on Lean Body Mass in Healthy Older Subjects During Bed Rest and Recovery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Nutrition</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Nutrition</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the effects of oral nutritional supplements (ONS) on attenuating the
      lean body mass (LBM) loss that occurs after bed rest.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total lean body mass</measure>
    <time_frame>Baseline to Study Day 10</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hand-grip strength</measure>
    <time_frame>Baseline, Study Day 10, Study Week 6 and 12</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Physical Performance Battery (SPPB)</measure>
    <time_frame>Baseline, Study Day 10, Study Week 6 and 12</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Isokinetic leg strength</measure>
    <time_frame>Baseline, Study Day 10 and Study Week 12</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>Screening Visits 1 and 3; Baseline; Study Days 2, 4, 6, 8 and 10; Study Weeks 3, 6, 9 and 12</time_frame>
    <description>Calculated BMI = weight/height2 (kg/m2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lower extremity lean mass</measure>
    <time_frame>Baseline, Study Day 10, Study Weeks 6 and 12</time_frame>
    <description>Measured by DXA; Change from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Control ONS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ONS without AN777</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational ONS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ONS containing AN777</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ONS without AN777</intervention_name>
    <description>2 servings a day</description>
    <arm_group_label>Control ONS</arm_group_label>
    <other_name>Commercially available ONS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ONS containing AN777</intervention_name>
    <description>2 servings a day</description>
    <arm_group_label>Investigational ONS</arm_group_label>
    <other_name>Investigational ONS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 60 to ≤ 79 years

          2. Body Mass Index (BMI) &gt;20 but ≤ 35 kg/m2.

          3. Short Physical Performance Battery (SPPB) score of &gt; 9 (fully functional with no
             mobility limitations).

          4. Triacylglyceride (TAG) level is ≤ 250 mg/dl, LDL cholesterol is ≤ 155 mg/dl, total
             cholesterol level is ≤ 250 mg/dl.

          5. Compliance with the various activity levels required for this study.

          6. Ankle brachial index within the normal range, between 1 and 1.4.

          7. Physical activity score within the 2008 Guidelines for Americans.

          8. Normal-good handgrip strength.

        Exclusion Criteria:

          1. Type I or Type II Diabetes Mellitus.

          2. Fasting blood glucose level of &gt;115 mg/dl.

          3. Major surgery, less than 6 weeks prior to enrollment in the study, or subject has
             planned elective surgery requiring 2 or more days of hospitalization.

          4. History of pressure ulcers.

          5. Stated history of Deep Vein Thrombosis (DVT), recent elevated D-dimer test, a positive
             ultrasound for DVT, pulmonary embolism, carotid atherosclerosis, transient ischemic
             attack (TIA), or stated hypercoaguable condition, or other clotting or bleeding
             disorders, or is currently prescribed blood thinners.

          6. Varicose veins that would result in significant discomfort while wearing TED hose
             and/or SCD.

          7. Stated autoimmune disease or active malignant disease.

          8. Estimated glomerular filtration rate is &lt; 50ml/min/1.73m2.

          9. Current significantly impaired liver function or hepatic enzyme tests are ≥2.5 times
             normal limit.

         10. Significant cardiovascular event ≤ 6 months prior to screening visit; or stated
             history of congestive heart failure.

         11. Untreated hypo- or hyper-thyroidism, or other endocrinopathies associated with
             excessive androgen secretion.

         12. Refractory anemia with hemoglobin value &lt;11.0 g/dl.

         13. Chronic, contagious, infectious disease, such as active tuberculosis, hepatitis B or
             C, or HIV.

         14. Current infection (requiring prescription antimicrobial or antiviral medication, or
             hospitalization), or has received corticosteroid treatment (with the exception of
             inhaled or topical steroids) in the last 3 months.

         15. Currently being prescribed pain/anti-inflammatory medication and/or is regularly
             consuming over the counter pain/anti-inflammatory medication for chronic, or
             persistent, pain, including but not limited to arthritic conditions, fibromyalgia, and
             continuous localized pain.

         16. History of allergy to any of the ingredients in the study products.

         17. Deleted

         18. Obstruction of the gastrointestinal tract precluding ingestion of the study product,
             inflammatory bowel disease, short bowel syndrome or other severe forms of
             gastrointestinal disease.

         19. Stated uncontrolled severe diarrhea, nausea or vomiting.

         20. Amputee.

         21. Actively pursuing weight loss or gain.

         22. Cannot refrain from taking medications/dietary supplements (all forms)/substances that
             could modulate metabolism or body weight.

         23. Cannot refrain from taking long chain n-3 polyunsaturated fatty acids (PUFA)
             (eicosapentaenoic acid (EPA) ± docosahexaenoic acid (DHA) ± α-linolenic acid (ALA)),
             or vitamin D, at levels that are significantly higher than the established Acceptable
             Macronutrient Distribution Range (AMDR), or recommended by the American Heart
             Association (500 mg/d total EPA+DHA), during the study.

         24. Cannot refrain from smoking or discontinue the use of nicotine (all forms including
             patches) or tobacco during the study.

         25. One or more metal implants.

         26. Currently diagnosis or a history of severe dementia or delirium, eating disorder,
             history of significant neurological or psychiatric disorder, alcoholism, substance
             abuse or other conditions that may interfere with study product consumption or
             compliance.

         27. Cannot abstain from alcohol use during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Owen Kelly, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott Nutrition</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences (UAMS)</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205-7199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Translational Research Institute for Metabolism and Diabetes</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of Translational Research in Aging &amp; Longevity</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77843-4253</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2014</study_first_submitted>
  <study_first_submitted_qc>March 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2014</study_first_posted>
  <last_update_submitted>July 7, 2016</last_update_submitted>
  <last_update_submitted_qc>July 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

